O-1A Guide
O-1A Judging Criterion: A biotech CEO's Guide for May 2024
This guide covers the latest strategies and evidence requirements. Learn what changed and how to position your case.
The judging criterion and its relevance to biotech executives
The judging criterion under 8 C.F.R. § 214.2(o)(3)(ii)(A) requires that the petitioner has participated, either individually or on a panel, as a judge of the work of others in the same or allied field of specialization. For biotech CEOs and senior executives, this criterion is frequently asserted but often inadequately documented. USCIS adjudicators require structured expert evaluation rather than routine business decisions or informal mentorship, and the distinction matters significantly in practice.
The threshold question is whether the evaluation involved genuine expert assessment of quality, merit, or significance within a formal institutional framework. A biotech executive who has served on a NIH study section, reviewed manuscripts for a peer-reviewed journal, or participated as a formal scientific panel reviewer for a government funding agency such as the National Science Foundation or the Advanced Research Projects Agency for Health has activities that directly satisfy the criterion. An executive whose only evaluation activities consist of internal performance reviews, investment committee decisions within their own company, or informal feedback to colleagues is in a substantially weaker position and should not assert the criterion without additional evidence development.
The practical significance of this criterion for biotech CEOs lies in the career trajectory of many executive-track scientists: as they move from active bench research into leadership roles, their publication record may thin while their evaluation responsibilities expand substantially. A former academic researcher who now leads a clinical-stage biotechnology company may not have published original research in several years but may have sat on multiple NIH study sections, reviewed dozens of manuscripts, and served on SABs for three or four organizations simultaneously. Identifying, documenting, and framing these evaluation activities in regulatory terms is a core task in building a strong O-1A petition for this professional population.
What the regulatory text requires
The regulatory requirement has three operative elements. First, the petitioner must have participated, meaning actual past or ongoing participation, not a general willingness or qualification to evaluate. Second, the evaluation must have been conducted individually or on a panel, which encompasses both solo review activities like journal peer review and collective evaluation bodies like grant review committees. Third, the work evaluated must be in the same or allied field as the petitioner's own field of extraordinary ability.
USCIS Policy Manual guidance clarifies that the criterion requires affirmative evidence of participation rather than evidence that the petitioner has the standing to evaluate others' work. A letter from a colleague attesting that the petitioner is a respected expert whose opinions others seek out does not satisfy the criterion. Documentation of actual evaluation activity within a formal institutional structure is required — for example, a letter from an NIH Scientific Review Officer confirming study section participation, or a letter from a journal editor confirming manuscript review. The distinction matters because expert letters in O-1A petitions often conflate reputational standing with criterion-specific evidence, and adjudicators are trained to identify and discount this conflation.
For the allied field requirement, biotech executives benefit from the broad interconnection among biotechnology, biomedical research, pharmaceutical development, clinical science, and regulatory affairs. A CEO with a background in protein biochemistry who reviewed NIH National Institute of Allergy and Infectious Diseases applications, evaluated manuscripts for translational medicine journals, or served on a scientific advisory board for an academic medical center program is participating in allied fields that appropriately support the judging criterion.
Evidence categories that satisfy the criterion
NIH study section participation is among the strongest possible evidence for the judging criterion. Study sections review competitive research grant applications, including R01 and R21 investigator-initiated proposals and K-series career development awards, under formal conflict-of-interest protocols with scores that directly determine funding outcomes. The NIH maintains administrative records of reviewer participation and will provide confirmation letters for immigration purposes upon request. A single round of study section participation covers multiple application reviews and can be documented with an NIH confirmation letter and a brief explanatory cover exhibit.
Peer review for peer-reviewed journals provides clean, verifiable evidence of evaluation activity when documented with a letter from the editorial office confirming participation. The most probative journal review records identify the journal by name, include information about the journal's standing and impact factor, indicate the approximate number of manuscripts reviewed, and cover a period long enough to establish regular rather than incidental participation. Review activity for journals such as Nature Biotechnology, Cell Chemical Biology, or the Journal of Clinical Investigation is more persuasive than equivalent activity for lower-tier publications.
External scientific advisory board membership is highly probative for senior executives because SAB participation is inherently selection-based, evaluation-focused, and formally constituted. A biotech CEO invited to serve on the SAB of a research institute, academic department, or other organization is there specifically because of recognized expertise and is expected to provide formal scientific assessments. Documentation should include the invitation letter, any board charter or scope-of-work documentation, and a letter from the relevant organization describing the petitioner's evaluation responsibilities and the criteria used to select SAB members.
Evidence USCIS consistently discounts
Internal evaluation activities, including performance reviews of company employees, internal research proposal review, and company-level scientific review committees, are consistently treated as insufficient to satisfy the judging criterion. USCIS draws a principled distinction between evaluation conducted for external institutional benefit and evaluation conducted as part of employment responsibilities for an employer's own purposes. Even when internal review involves sophisticated scientific assessment by a highly qualified evaluator, it does not satisfy the criterion because it is directed at the employer's proprietary interests rather than at the field at large.
Conference session chairing presents a similar documentation challenge. Session chairs at scientific conferences manage logistics, facilitate discussion, and introduce speakers, but typically do not evaluate the scientific merit of presentations in any formal sense. Where session chairing is submitted as judging criterion evidence, it should be accompanied by documentation showing that the session chair role involved substantive evaluation, such as reviewing abstract submissions, ranking presentations, or participating in award selection processes. Without that additional documentation, session chairing is treated as facilitation rather than evaluation.
Informal advisory roles, mentorship activities, and consulting engagements, even those involving substantial technical review of others' work, generally do not satisfy the criterion because they lack the formal institutional structure the regulation contemplates. A CEO who regularly advises biotech startups, provides technical feedback to university research groups, or consults on scientific design for other companies is evaluating others' work but in a context where the evaluation was not formally constituted by an institution and is not documented in records that USCIS can evaluate against regulatory standards.
Borderline cases and framing strategies
The most difficult judging criterion situations involve evaluation activities that are genuine and extensive but conducted through forums with ambiguous documentation. Private-sector venture fund scientific diligence is a common example: an executive who sits on an investment committee, evaluates the scientific merit of potential portfolio companies, and provides expert opinions that inform substantial investment decisions is clearly engaged in formal expert evaluation. However, the confidential and proprietary nature of the process means the available documentation may be limited to a general description of the role rather than a comprehensive exhibit record.
For executives whose evaluation activities are primarily private-sector, the recommended strategy is to build the best available documentation from private-sector sources, specifically confidentiality-compliant letters that describe the evaluation role and the expertise required without revealing proprietary information, and to supplement with whatever public-sector evaluation credentials exist. A combination of NIH ad hoc review credits and substantial private-sector SAB participation creates a record that anchors the criterion in verifiable public institutional evidence while reflecting the full scope of evaluation activities.
Where judging criterion evidence is thin despite genuine professional engagement, practitioners should weigh whether to assert the criterion at all versus building a stronger petition on a smaller set of well-documented criteria. The O-1A requires meeting at least three of the regulatory criteria, and a petition built around original contribution, critical role, and high salary can be legally sufficient and more persuasive than a petition that asserts five criteria with uneven evidentiary support. Forcing a weak criterion claim into a petition can create credibility issues that affect how adjudicators evaluate the stronger criterion evidence.
Pre-submission audit checklist
Before finalizing the judging criterion evidence, verify that each evaluation activity submitted includes documentation of the institutional context, including the forum, its standing in the field, and the formal nature of the evaluation process. Check that each exhibit establishes the petitioner's specific role as evaluator rather than as presenter, organizer, or general advisor. Confirm that the field or sub-field being evaluated is characterized in language that aligns with the field of extraordinary ability defined elsewhere in the petition.
Review the expert letters for targeted references to the judging activities. An expert letter that notes the petitioner was selected by a named institution to serve in an evaluation capacity adds a credibility dimension that institutional documentation alone cannot provide. Expert letter writers who can speak to why they or their institution sought out the petitioner for evaluation responsibilities, whether because of specific scientific expertise, field standing, or recognized excellence, strengthen the criterion argument substantially.
Audit the judging evidence against common RFE patterns for O-1A petitions in biological sciences. Common RFE subjects include insufficient documentation of the forum's standing, incomplete documentation of the petitioner's specific evaluation role as distinguished from other roles at the same institution, and failure to establish that the evaluation activity was in the same or allied field. A proactive strategy is to include a brief exhibit map in the cover letter that identifies each judging exhibit and explains specifically how it satisfies the regulatory requirement, preempting the most common questions before they arise. A petition that anticipates and pre-addresses these gaps in the initial submission is less likely to generate an RFE and more likely to receive a favorable initial adjudication on the first pass.